National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
340
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

PATHOGEN DESCRIPTION

Streptococci are spherical or ovoid bacteria that grow in pairs or chains of varying lengths. They are gram-positive, non-spore-forming, catalase-negative, and ordinarily nonmotile. They have complex and variable nutritional requirements.

Taxonomically, these organisms belong to the family Sreptococcaceae, genus Streptococcus, of which there are 21 identified species. When streptococci are cultivated on blood agar plates, they may produce complete (beta) hemolysis, partial (alpha) hemolysis, or no (gamma) hemolysis. More precise differentiation of streptococci can be made by immunologic means. The organisms may be separated into serogroups by means of antigenic differences in the cell wall carbohydrates or teichoic acids. The group A streptococcus, also known as Streptococcus pyogenes, is facultatively anaerobic, beta-hemolytic (with very rare exceptions), and contains in its cell wall a group-specific carbohydrate composed of rhamnose and N-acetyl-glucosamine. There are a number of other important substances expressed on the streptococcal surface. These include lipoteichoic acid, the principal ligand responsible for adherence of GrAS to epithelial surfaces, and a variety of proteins designated as M, T, and R. Of these, by far the most important is M protein.

M protein is the major virulence antigen of GrAS. Strains rich in this protein are resistant to phagocytosis by polymorphonuclear leukocytes, multiply rapidly in fresh human blood, and are capable of initiating disease. Strains lacking M protein are avirulent. Group A streptococci may be divided into serotypes on the basis of antigenic differences in M protein molecules. Over 70 such serotypes are currently recognized. Human immunity to streptococcal infection is based on the development of type-specific opsonic antibodies directed against the anti-phagocytic moiety of M protein. In rare instances, cross-protection by antibody to one type against organisms of a heterologous type has been demonstrated.

The M protein molecule penetrates the cell wall; this configuration localizes the type-specific antigen on the tips of hair-like fimbrillae protruding from the cell surface. The manner in which M protein exerts its anti-phagocytic effect is under investigation. The protein prevents interaction of the streptococcal cell wall with complement components, an effect that is enhanced by the ability of M protein to precipitate fibrinogen directly onto the bacterial surface. This protective effect is nullified by the presence of adequate concentrations of type-specific antibody.

T protein serves as the basis for a subsidiary typing system for GrAS. Another important somatic component of the streptococcus is the hyaluronic acid capsule. This capsule is also anti-phagocytic and serves as an auxiliary virulence factor.

For many years, it has been recognized that the ability to initiate AGN is limited to strains of certain GrAS serotypes (e.g., types 1, 4, 12, 49, 55, and a few others). Although this distinction between nephritogenic and nonnephritogenic GrAS is well established, there has been considerably more controversy over the issue of whether GrAS vary

Page
340
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)